Pharmaceuticals

BUCHANG PHARMA

China National Pharmaceutical Co. and BCI Pharmaceutical Co. Sign Comprehensive Strategic Agreement

BUCHANG PHARMA released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 2.579 B, actual EPS CNY 0.3045

BUCHANG PHARMA released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 3.406 B, actual EPS CNY -0.4829

BUCHANG PHARMA released FY2025 Annual Earnings on April 27 After-Market (BJT), with actual revenue of CNY 11.88 B and EPS of CNY 0.3416

BUCHANG PHARMA to Release FY2026 Q1 Earnings on April 28 After-Market BJT

BUCHANG PHARMA FY2025 Annual Earnings Release on April 28, 2026 After-Market (BJT)

BUCHANG PHARMA released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 8.469 B, actual EPS CNY 0.8208

BUCHANG PHARMA released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 2.805 B, actual EPS CNY 0.2274

BUCHANG PHARMA FY2025 Q3 Earnings Release on October 30, 2025 After-Market (BJT)

BUCHANG PHARMA released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), Actual Revenue: CNY 5.664 B, Actual EPS: CNY 0.5934

BUCHANG PHARMA released FY2025 Q2 earnings on August 27 During-Market BJT, actual revenue CNY 2.879 B, actual EPS CNY 0.3035

BUCHANG PHARMA to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Luzhou Buchang Grants Philippine Company Exclusive Agency for Injection Efaparoepoetin Alfa

Baichang Pharmaceutical Expected to See Significant Profit Growth in 2025 Half-Year

Bachuang Pharmaceutical Subsidiary Obtains Registration Certificate for Quadrivalent Influenza Vaccine

Shareholders of Stepping Long Pharmaceutical's Subsidiaries Transfer Shares for Free

Stephens Pharmaceutical Subsidiary Receives NMPA Registration Certificate for Lacosamide Injection

StepLong Pharmaceutical Subsidiary Invests in Setting Up Shaanxi Steplong MediTech Pharmaceutical

Bachuang Pharmaceutical Approves Mid-Year Dividend Plan for 2025

Steplong Pharmaceutical's Subsidiary Receives Acceptance for Adalimumab Injection Registration Application

603858

688331

600141

Since 2026, the trend of share buybacks among listed companies has continued. In January, several A-share companies implemented buybacks, including BUCHANG PHARMA and Xingfa Chem. Huasheng Lithium Battery, RemeGen, and Yiyi Co., Ltd. adjusted their buyback prices due to stock prices exceeding the buyback limit. The main reason for the companies' buybacks is based on confidence in future development prospects, with repurchased shares often used for employee stock ownership plans or equity incentives

Wallstreetcn

RemeGen

Xingfa Chem

Many listed companies have taken repurchase actions in the first month of the new year

BUCHANG PHARMA announced that the company's director Zhao Chao resigned on October 17, 2025, for personal reasons, with the original term set to end on June 28, 2027. After resigning, Zhao Chao will continue to serve as president and does not hold any shares in the company. The company will complete the election of a new director as soon as possible. The company expresses its gratitude for Zhao Chao's contributions during his tenure

Zhitong

BUCHANG PHARMA: Director Zhao Chao resigns for personal reasons

BUCHANG PHARMA's subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. has signed a technical service contract with WuXi AppTec, entrusting it to conduct pharmacokinetic and toxicology tests. This collaboration will help expand the company's drug research and development capabilities, save time and costs for clinical trials, and ensure the smooth progress of projects

BUCHANG PHARMA's subsidiary signs a technical service contract with WuXi AppTec

According to the Zhitong Finance APP, BUCHANG PHARMA announced that its affiliated company Guangzhou Qilekang Digital Health Medical Technology Co., Ltd. (hereinafter referred to as "Qilekang Digital Medical") has a substantial controlling company POMDOCTOR LIMITED Shiliu Cloud Medical Co., Ltd. (hereinafter referred to as "Shiliu Cloud Medical") which will be listed on the NASDAQ stock exchange in the United States using the VIE model on October 8, 2025 (New York time), with the stock code: POM

BUCHANG PHARMA: Pomegranate Cloud Medical is listed on the NASDAQ stock exchange in the United States

On October 13th, BUCHANG PHARMA announced that its wholly-owned subsidiary Shandong Danhong Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate for ibuprofen sustained-release capsules approved and issued by the National Medical Products Administration. The indications are for the relief of mild to moderate pain such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea. It is also used for fever caused by the common cold or influenza

BUCHANG PHARMA: Obtained the drug registration certificate for ibuprofen sustained-release capsules

BUCHANG PHARMA announced that it will jointly invest 4.9 million yuan with Jinan Hengde Technology and Shanghai Guoding Technology to establish two new companies to promote the development of its holding subsidiary Shanghai Hepu Medical Technology Co., Ltd

BUCHANG PHARMA: Plans to jointly invest with Jinan Hengde Technology and Shanghai Guoding Technology to establish two new companies

BUCHANG PHARMA's wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. This drug is used for the treatment of influenza A and B in adults and children over 1 year old, and can be used for influenza prevention in adolescents over 13 years old. It is expected that the sales in urban pharmacies in China will be 152 million yuan, 824 million yuan, and 776 million yuan from 2022 to 2024, respectively. The company's R&D investment in this project is approximately 12.9612 million yuan

BUCHANG PHARMA: Wholly-owned subsidiary obtains drug registration certificate for Oseltamivir Phosphate Capsules

According to the Zhitong Finance APP, BUCHANG PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 5.664 billion yuan, a year-on-year increase of 4.27%; net profit attributable to the parent company was 628 million yuan, a year-on-year increase of 171.24%; net profit excluding non-recurring gains and losses was 619 million yuan, a year-on-year increase of 180.04%; basic earnings per share were 0.5934 yuan. The company plans to distribute a cash dividend of 3.90 yuan (tax included) for every 10 shares

BUCHANG PHARMA released its semi-annual performance, with a net profit attributable to the parent company of 628 million yuan, a year-on-year increase of 171.24%

BUCHANG PHARMA announced that its holding subsidiary Shandong Danhong intends to sign a technology transfer contract with the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, with a total transfer price of 15 million yuan. The contract involves the ownership of the technology for the Traditional Chinese Medicine Erzhi Regulating Menstruation Optimization Formula, aiming to enrich the product research and development pipeline and ultimately achieve industrial-scale production of the new drug. This transaction does not constitute a related party transaction and does not constitute a major asset reorganization

BUCHANG PHARMA: Shandong Danhong plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for 15 million yuan

BUCHANG PHARMA(603858.SH)